CASRAI Dictionary

Author: MCP Service

  • Machine-Actionable Data Management Plans: What Changes

    Data management plans (DMPs) have traditionally been static, prose documents written once at proposal stage and rarely opened again. That is changing. Funders, repositories and institutional systems are converging on machine-actionable data management plans (maDMPs) — DMPs structured so that software, not just people, can read and act on them. The shift is being driven by the RDA DMP Common Standard, a specification from the Research Data Alliance that turns free-text plans into structured, exchangeable data. This article explains what “machine-actionable” means in practice, what the standard actually changes, which tools implement it, and why funders are pushing the sector in this direction.

    What “Machine-Actionable” Actually Means

    A conventional DMP is a Word document or PDF: a human writes prose describing what data will be collected, how it will be stored, and where it will end up. A reviewer reads it once, files it, and rarely revisits it. Nothing in that document can be queried, validated automatically, or passed to another system without someone re-typing it.

    A machine-actionable DMP replaces (or accompanies) that prose with structured fields — dataset descriptions, distribution details, metadata standards, licences, repository identifiers — encoded so that a repository, funder portal, or research information system (CRIS) can parse them directly. The foundational framing paper, Ten Principles for Machine-Actionable Data Management Plans (Miksa, Simms, Mietchen & Jones, PLOS Computational Biology, 2019, cited over 130 times), describes the goal as embedding DMPs in existing research workflows so parts of the plan can be generated, validated and updated automatically rather than retyped at every stage.

    • Structured, not free-text — fields for dataset type, format, volume, access conditions and repository are discrete and machine-parseable.
    • A living document — updated through the project lifecycle rather than filed once and forgotten.
    • Interoperable — exportable between DMP tools, repositories, CRIS platforms and funder systems without manual re-entry.
    • Partially automatable — some fields (e.g. ORCID iDs, grant metadata, repository policies) can be pre-filled from connected systems.

    Definitions of related research-data terms are catalogued in the CASRAI Dictionary.

    The RDA DMP Common Standard: What It Changes

    The RDA DMP Common Standard for Machine-actionable Data Management Plans, developed by an RDA working group, defines a shared JSON schema for representing a DMP’s core elements: project and funder metadata, one or more datasets, each dataset’s distribution (repository, licence, access level), and the metadata standards applied to it. The schema is published and version-controlled openly on GitHub, so any tool builder can implement it without licensing constraints.

    Before a common schema existed, each DMP tool stored plans in its own proprietary structure. A plan created in one system could not be meaningfully exported to another, and funders could not aggregate structured data across grant portfolios without manual extraction. The Common Standard changes that by giving every participating tool the same underlying data model, so a DMP authored in one platform can, in principle, be exported as valid maDMP JSON and ingested by another.

    This matters most at the points where a DMP currently has to be re-keyed: submitting to a funder portal, registering a dataset with a repository, and reporting compliance at project close. A structured, standard-conformant DMP removes several of those manual hand-offs.

    Which Tools Implement the Standard

    Three tools dominate current maDMP practice, each maintained by a different non-profit research-infrastructure organisation:

    Tool Maintaining organisation Primary user base maDMP support
    DMPonline Digital Curation Centre (DCC), University of Edinburgh UK and international institutions API and structured export aligned to the RDA Common Standard
    DMPTool California Digital Library (CDL/UC3) US universities and federal-grant researchers Templates mapped to funder requirements; RDA-aligned export in progress
    ARGOS OpenAIRE, originally built under the EU FAIRsFAIR project Horizon Europe and EOSC-affiliated researchers Native maDMP JSON, direct repository and metadata-standard linking

    DMPonline and DMPTool both originated as template-driven questionnaires aligned to specific funder wording, then layered structured export on top as the Common Standard matured. ARGOS was built later, directly on the RDA schema, as part of the EU-funded FAIRsFAIR (“Fostering FAIR Data Practices in Europe”) project, which is why it links more natively to repositories and metadata standards rather than treating them as free-text fields. Institutions choosing between them should check which one their funder or repository already exchanges data with, rather than assuming full interoperability across all three.

    Why Funders Are Moving in This Direction

    Funders adopted DMP requirements originally to make researchers think about data stewardship before, not after, the fact. Horizon Europe requires a DMP as a formal deliverable for data-generating projects, due within six months of the project start and updated at least at the mid-term and final reporting points — a recurring obligation that is far easier to track programmatically than by re-reading prose each time. The US National Institutes of Health introduced its Data Management and Sharing Policy in 2023, requiring a DMS plan for every funded project involving scientific data, which has pushed US institutions toward tools that can validate plans at scale rather than review them manually.

    For funders managing thousands of active grants, machine-actionable plans mean compliance can be checked computationally — flagging, for instance, a dataset with no named repository or an access licence inconsistent with funder policy — instead of requiring programme officers to re-read each document individually. For research administrators, the practical benefit is fewer duplicate data-entry tasks across grant systems, repositories and institutional CRIS platforms, and DMPs that can be audited at renewal or close-out without starting from scratch.

    Common Questions About Machine-Actionable DMPs

    What is a machine-actionable data management plan?

    A machine-actionable data management plan (maDMP) is a DMP whose content is structured — typically as JSON conforming to the RDA DMP Common Standard — so that repositories, funder systems and research information platforms can read, validate and act on it automatically, rather than relying on a human re-reading free-form prose.

    What should a data management plan include?

    A DMP typically describes the types and volume of data to be generated, metadata standards applied, storage and security arrangements, ethical and legal considerations, roles and responsibilities, and the data-sharing and long-term preservation plan, including the intended repository and access licence.

    Why is research data management important?

    Sound research data management improves the integrity, reproducibility and reuse value of research outputs. It ensures data remain findable and accessible after a project ends, satisfies funder and publisher mandates, and reduces the risk that valuable data become unusable or unrecoverable once the original team disperses.

    The direction of travel is clear: DMPs are moving from a one-off compliance document to structured metadata that persists and updates across a project’s life, feeding repositories, funder reporting and institutional systems without re-transcription. Institutions that adopt an RDA-aligned tool now — DMPonline, DMPTool or ARGOS — are better positioned as more funders begin to require, rather than merely accept, structured plans.

  • NIH Grant Application Cap: What Changed and Why

    The NIH grant application cap is no longer a single rule. Since September 2025, principal investigators (PIs) have faced a firm limit on how many applications they can submit each year. As of June 2026, NIH is now consulting on a second, separate limit — this time on how many grants a PI can hold at once. The two policies are frequently conflated in coverage, but they operate on different mechanisms, timelines, and parts of a research office’s workload.

    Two different NIH caps, explained

    The first cap is already in force. Effective 25 September 2025, NIH limits each principal investigator (PI) or multiple-PI (MPI) team member to a maximum of six new, renewal, resubmission, or revision applications per calendar year. The limit applies per PI, not per institution, and resubmissions count toward the total — so a PI who submits three new applications and then resubmits two after a first review has used five of six slots.

    The cap excludes R13 conference grants and T-series training activity codes. Critically for multi-PI labs, it also excludes collaborative submissions where a researcher is listed only as a co-investigator or other senior/key personnel rather than as PI or MPI. NIH told Inside Higher Ed that only 1.3% of applicants submitted more than six PI/MPI applications in 2024 — the vast majority of investigators were never going to be affected by the ceiling itself.

    The second cap is still a proposal. On 8 June 2026, NIH published NOT-OD-26-086, an RFI seeking comment on a policy that would cap the number of simultaneous Research Project Grants (RPGs) a single PI can hold, with options of two, three, or four concurrent awards. This is a portfolio cap, not a submission cap — it would restrict how many active RPGs a PI can run at once, regardless of how many applications they submitted to get there. Science reported that a three-RPG limit was modelled to free roughly $2 billion and support around 3,020 additional investigators, while a two-RPG cap was modelled to free a larger sum, cited at roughly $3.5 billion. The comment period is open until 3 August 2026.

    Feature Submission cap (in force) Concurrent-award cap (proposed)
    Status Active policy since 25 Sept 2025 RFI (NOT-OD-26-086), comments open to 3 Aug 2026
    What it limits Applications submitted per calendar year RPGs held simultaneously per PI
    Threshold 6 applications (new, renewal, resubmission, revision combined) 2, 3, or 4 concurrent RPGs (options under review)
    Excludes R13 conference grants; T-series training codes; co-I/senior-key-personnel roles Not yet finalised
    Stated rationale Reduce review-system overload, curb AI-assisted mass submission Broaden funding distribution across more investigators

    Why NIH is doing this: the portfolio-management rationale

    Both policies are framed by NIH as portfolio-management measures rather than budget cuts. The submission cap arrived alongside a companion policy on AI-generated content: NIH will not treat applications “substantially developed by AI” as original ideas of the applicant, and post-award detection can trigger a referral to the Office of Research Integrity alongside cost disallowance or termination. NIH told reporters the pairing was meant to stop high-volume, AI-assisted submissions from overwhelming peer review — not to reduce the number of investigators it funds.

    The concurrent-award RFI targets a different bottleneck: funding concentration. NIH’s own modelling, reported by Science, suggests a relatively small number of well-funded PIs hold a disproportionate share of active RPGs, and capping simultaneous awards at two, three, or four would redistribute billions toward early- and mid-career investigators who currently hold zero or one RPG — a structural-limit approach also used in eligibility rules at other national funders.

    • The submission cap manages review-system load.
    • The proposed concurrent-award cap manages funding concentration.
    • Neither policy, as currently described, changes the NIH salary cap (set at $228,000 for 2026), which governs allowable reimbursed salary under an award, not how many awards a PI may hold.

    Answer-first: common questions on the NIH grant application cap

    What is the maximum number of applications for NIH?

    Since 25 September 2025, each principal investigator or multiple-PI team member may submit a maximum of six new, renewal, resubmission, or revision applications per calendar year. Conference (R13) and training (T-series) applications are excluded, as are submissions where the researcher is listed only as a co-investigator rather than PI or MPI.

    What is the new NIH cap for 2026?

    There are two distinct 2026 developments, and they are easily confused with the unrelated NIH salary cap ($228,000 for 2026). The application-submission cap (six per year) took effect in 2025 and remains active. In June 2026, NIH separately opened an RFI, NOT-OD-26-086, proposing to cap how many concurrent RPGs a single PI may hold, with comments due by 3 August 2026.

    Does the application cap include co-investigators and multi-PI teams?

    No. The six-application limit counts applications where a researcher is listed as PI or MPI. Collaborative submissions naming a researcher only as a co-investigator or other senior/key personnel do not count toward that individual’s cap, which is the main structural workaround available to multi-PI labs today.

    When does the NIH RFI comment period close?

    The public comment period for NOT-OD-26-086, the proposal to cap concurrent RPGs per PI, closes on 3 August 2026. Institutions, scientific societies, and individual investigators can submit input directly to NIH before that deadline, ahead of any final policy decision.

    Practical workarounds for multi-PI labs

    Research administrators advising multi-PI groups have several concrete levers under the current (submission-cap) rules:

    • Restructure authorship roles deliberately. Only PI/MPI-listed applications count toward the cap, so labs with more ideas than headroom can route some proposals through a co-investigator or senior/key personnel role for researchers who have used their six slots.
    • Sequence resubmissions carefully. Resubmissions count toward the same total as new submissions, so a PI planning two new R01s and a resubmission must track all three against the ceiling from the start of the cycle, not treat resubmission as “free”.
    • Front-load the strongest applications. With a hard ceiling of six, strategy shifts from “submit broadly” toward prioritising the highest-confidence proposals for limited PI/MPI slots, using non-PI collaborative roles for higher-risk ideas.
    • Track activity codes against the exclusion list. R13 conference grants and T-series training awards fall outside the cap entirely; labs running these should confirm applications aren’t wrongly counted against the six-application limit.
    • Watch the RFI, not just the final rule. With the concurrent-award cap open for comment until 3 August 2026, institutions with PIs holding three or more active RPGs have a narrow window to model exposure before any threshold is finalised.

    Implications for institutions and research offices

    For sponsored-programmes offices, the practical burden shifts from “how many can we submit” to “how do we allocate scarce PI slots.” Portfolio dashboards need to track each PI’s six-application count in real time, since resubmissions and revisions from earlier in the year silently consume capacity. It also raises internal equity questions: early-career PIs who have not yet hit historical submission volumes are effectively unconstrained, while a small number of high-output senior PIs may need support prioritising which six applications matter most.

    If the concurrent-award cap is adopted, the implication is larger still. Research offices would need to model which currently-funded PIs already exceed a prospective two-, three-, or four-RPG ceiling, and plan succession — including early-career co-investigators who could be elevated to PI on a renewal. Both policies also interact with the NIH Grants Policy Statement’s existing budget-deviation rules, under which cost-category deviations of 25% or more from an approved budget may require prior sponsor approval; institutions restructuring PI roles to manage the cap should route resulting scope changes through that existing mechanism.

    What’s next

    The six-application submission cap is settled policy, unlikely to be revisited before NIH gathers a full year of compliance data. The concurrent-award RFI is the item to watch: with comments open until 3 August 2026 and modelled effects ranging from roughly $2 billion (a three-RPG limit) to roughly $3.5 billion (a two-RPG limit) in redistributed funding, the threshold NIH eventually chooses will materially change how research-intensive institutions structure PI status on renewals. Research administration offices tracking funder-mandate changes should treat the comment period as an active planning window, not a wait-and-see notice — the final policy is likely to arrive with limited transition time once published.

  • Data Provenance: Tracking Research Data to Publication

    Research funders increasingly ask not just whether a dataset is open, but where it came from. Data provenance is the discipline of documenting a dataset’s origin, custody, and every transformation it undergoes between collection and publication — a distinct concern from data lineage, which maps only the technical pathway data takes through systems. As data management plans, repository deposits, and AI-training-data audits come under closer scrutiny, provenance metadata is becoming the connective tissue between “collected” and “citable.”

    What Is Data Provenance?

    Data provenance is the historical record of a dataset’s origin, custody, and processing history — who created or collected it, under what conditions, and what happened to it before it reached its published form. It functions as a chain of custody: not a single field in a metadata record, but a continuous trail spanning collection instruments, transformation scripts, quality checks, and every hand the data passed through.

    This differs from anonymisation or privacy-preserving techniques, which govern what can be disclosed about a dataset’s contents. Provenance governs what can be verified about a dataset’s history — a governance question, not a disclosure-control one.

    Data Provenance vs Data Lineage

    The two terms are frequently used interchangeably, but the ELIXIR Research Data Management Kit (RDMkit) draws a useful distinction: lineage traces the technical movement of data between systems — extract, transform, load, output — while provenance adds the contextual and authorship layer: who authorised each step, why it happened, and under what licence or methodology.

    • Data lineage answers: which pipeline stages did this data pass through, and in what order?
    • Data provenance answers: who is accountable for each stage, and can that history be trusted and cited?

    In practice, a well-built pipeline produces both: lineage as the operational map, provenance as the governance record layered on top of it.

    Provenance Standards: W3C PROV, RDA and RO-Crate

    Provenance only becomes machine-actionable — and therefore auditable at scale — once it is captured against a shared model rather than free text. The W3C PROV family (PROV-DM, PROV-O, PROV-N) is the reference data model, formally recommending how to describe “entities,” “activities,” and “agents” so provenance graphs can be exchanged between systems. The Research Data Alliance (RDA) has convened interest groups aligning disciplinary metadata practices with PROV-DM, and repository-facing specifications build on top of it.

    Standard / Framework Steward What It Captures
    PROV-DM / PROV-O / PROV-N W3C Formal graph model of entities, activities and agents; RDF/OWL-serialisable provenance
    RO-Crate Research Object community (schema.org-based) Packages a dataset with its licence, workflow-run history and provenance in one archive
    ISO 19115-2 ISO Lineage extension for geographic and imagery metadata
    DataCite Metadata Schema DataCite Related-identifier relationship types (IsDerivedFrom, IsSourceOf) linking a dataset DOI to its origin and outputs

    Discipline-specific profiles then sit on top of these: FAIRsharing and RDA’s standards directory catalogue hundreds of provenance and metadata schemas so groups do not reinvent the model for each field.

    Building a Custody Chain from Collection to Publication

    A defensible provenance record follows the dataset through five stages, each logged with enough detail that a third party could reconstruct the history without contacting the original team.

    • Collection: instrument or method, collector identity (an ORCID iD is the practical anchor), date, and location captured at source.
    • Transformation: every cleaning, normalisation, aggregation or filtering step logged with the tool and version used.
    • Review: who validated the data, what checks were applied, and what was flagged or excluded.
    • Deposit: registration in a repository with a persistent identifier — a DataCite or CrossRef DOI — and an ROR identifier for the responsible institution.
    • Citation and reuse: downstream citations captured so the provenance trail extends forward into the published research output that relies on it.

    Contributor-role taxonomies help name accountability at each stage. The CRediT contributor role of “Data Curation,” for example — a taxonomy CASRAI originated in 2014 and which is now stewarded by NISO as ANSI/NISO Z39.104-2022 — gives institutions a controlled vocabulary for naming who performed which custody step, complementing PROV-O’s more technical entity/activity/agent model. Research administrators building data management plans can pair the two: CRediT roles for human accountability, PROV-DM for machine-actionable history.

    Common Questions About Data Provenance

    What is data provenance?

    Data provenance is the documented history of a dataset’s origin and custody — who collected it, under what method, and what transformations it underwent before use. It functions as a chain of custody, supporting authenticity checks, quality auditing, and reproducibility of any research output that relies on the data.

    What is data provenance vs lineage?

    Data lineage maps the technical route data takes between systems — extraction, transformation, loading. Data provenance adds the accountability layer: who authorised each step, why it occurred, and under what licence. Lineage is the operational map; provenance is the governance record built on top of it.

    What are the two classes of data provenance?

    Provenance literature typically distinguishes backward (retrospective) provenance, which reconstructs a dataset’s origin and history after the fact, from forward (prospective) provenance, which records how data is expected to move and transform in a defined future workflow before it happens.

    What does provenance mean?

    Outside data contexts, provenance refers to the documented history of ownership or origin of an object — the term used to authenticate artworks and manuscripts. Applied to research data, the same principle holds: a verifiable record of origin that supports trust, exactly as a chain of custody supports evidentiary trust in other domains.

    Why Provenance Completes FAIR: Implications for Institutions

    The FAIR data principles (Findable, Accessible, Interoperable, Reusable) are frequently treated as a checklist for open deposit, but the Reusable facet explicitly requires more than a licence tag. Principle R1.2 states that “(meta)data are associated with detailed provenance” — a sub-principle that is easy to satisfy nominally and hard to satisfy meaningfully. A dataset can be technically Findable and Accessible while its provenance metadata is a single free-text sentence, which leaves reproducibility unverifiable in practice.

    This gap matters more as scrutiny of dataset origin intensifies elsewhere. MIT Media Lab’s audit of over 1,800 AI training datasets found licence omission or miscategorisation in more than two-thirds of cases — a warning sign for any field, including research data management, that treats provenance as an afterthought rather than a captured-at-source discipline.

    For institutions building or refreshing data management plans under UKRI or Horizon Europe funding requirements, the practical implication is straightforward: provenance capture belongs at collection time, encoded against PROV-DM or an equivalent model, not reconstructed retrospectively when a journal, repository, or auditor asks for it. Research administrators, repository managers, and publishers who build custody-chain logging into their research administration workflows now will find FAIR compliance — and reproducibility review — considerably less costly later.

  • UK Policy Framework for Health and Social Care Research: A Governance Primer

    What Is the UK Policy Framework for Health and Social Care Research?

    The UK Policy Framework for Health and Social Care Research is the single set of standards that governs how health and social care research is designed, sponsored, approved, and reported across England, Northern Ireland, Scotland, and Wales. It was published by the Health Research Authority (HRA) and the four UK health departments in October 2017, replacing the separate national Research Governance Frameworks that each country had previously maintained since the early 2000s.

    For research administrators, the practical significance is that a single rulebook now applies wherever the study touches NHS or Health and Social Care (HSC) patients, service users, data, or tissue — regardless of whether the funder is a UK research council, a charity, a university, or a life sciences company. Any study that falls within scope requires a designated sponsor, appropriate ethical and regulatory approval, and proportionate ongoing oversight before, during, and after delivery.

    The 19 Principles: Structure and Scope

    The framework is built around 19 principles of good practice, split into two tiers. The first 15 apply to all health and social care research; the final four apply only to interventional research, where treatment, care, or service delivery is changed for research purposes.

    • Principles 1–15 (all research): Safety, Competence, Scientific and Ethical Conduct, Patient/Service User/Public Involvement, Integrity/Quality/Transparency, Protocol, Legality, Benefits and Risks, Approval, Information about the Research, Accessible Findings, Choice, Insurance and Indemnity, Respect for Privacy, and Compliance.
    • Principles 16–19 (interventional research only): Justified Intervention, Ongoing Provision of Treatment, Integrity of the Care Record, and Duty of Care.

    Principle 9 (Approval) and Principle 10 (Information about the Research) are the two most operationally significant for grant-funded studies: no study may start until it has a favourable Research Ethics Committee (REC) opinion where required, and every study — bar limited waivers — must be registered publicly before recruitment begins to avoid research waste.

    Every study in scope must have a sponsor: the individual, organisation, or partnership that takes overall responsibility for proportionate, effective arrangements to set up, run, and report the research. For non-commercial, grant-funded studies the sponsor is normally the employer of the chief investigator; for commercial studies it is normally the funder. Crucially, an employer or funder does not become the sponsor automatically — the role must be explicitly accepted and documented.

    Under the framework, the sponsor’s overall responsibility includes:

    1. Identifying and addressing poorly designed research and ensuring proposals are scientifically sound, safe, ethical, legal, and feasible for the duration of the study.
    2. Satisfying itself that investigators, the research team, and research sites are suitable.
    3. Documenting agreed roles, responsibilities, and any delegation of sponsor tasks.
    4. Ensuring adequate insurance or indemnity is in place to cover liabilities arising from the research.
    5. Ensuring public registration before the study starts and accessible reporting of data, tissue, and findings afterwards.
    6. Confirming REC and any other required regulatory approvals are secured before the research begins.
    7. Maintaining adequate finance, risk management, and data management arrangements throughout delivery.
    8. Keeping effective monitoring, progress-reporting, and safety-reporting procedures in place.

    Sponsors of clinical trials of investigational medicinal products (CTIMPs) carry additional statutory duties under the Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031, as amended). Universities and colleges are expected to accept the sponsor role for educational research conducted by their own students, unless the student’s NHS or social care employer prefers to take it on.

    REC Review and NHS/HRA Approval

    Research Ethics Committee review is the framework’s central quality gate. No study may start unless a REC — and, where applicable, another approval body such as the Medicines and Healthcare products Regulatory Agency (MHRA), the Human Fertilisation and Embryology Authority (HFEA), or the Administration of Radioactive Substances Advisory Committee (ARSAC) — has issued a favourable opinion on the protocol and supporting documentation.

    In England, REC review is bundled with the confirmation of capacity and capability at NHS organisations through the HRA Approval process, which replaced separate local Research and Development (R&D) sign-off across NHS trusts in 2016. Applications are submitted and tracked through the Integrated Research Application System (IRAS). This single-approval model is one of the framework’s clearest efficiency gains over the pre-2017 regime, in which sponsors could face duplicated ethics and governance review at every participating site.

    The following table summarises the approval routes that sit alongside REC review, depending on study type.

    Study type Additional approval body Legal basis
    Clinical trials of investigational medicinal products (CTIMPs) MHRA Medicines for Human Use (Clinical Trials) Regulations 2004
    Studies using ionising radiation ARSAC Ionising Radiation (Medical Exposure) Regulations
    Research involving human embryos or gametes HFEA Human Fertilisation and Embryology Act 1990
    Research using confidential patient information without consent Confidentiality Advisory Group (CAG) Health Service (Control of Patient Information) Regulations 2002

    Governance Across the Four UK Nations

    Because health and social care are devolved matters, the framework is implemented by a different lead body in each nation, though the 19 principles and sponsor duties remain constant UK-wide.

    • England: Health Research Authority (HRA) — covers health and adult social care research.
    • Northern Ireland: Department of Health (Northern Ireland) — covers health and social care.
    • Scotland: Scottish Government Health and Social Care Directorates — covers health and adult social care.
    • Wales: Department for Health, Social Care and Early Years, operationalised through Health and Care Research Wales.

    Underlying legislation also varies by nation. Common UK-wide law includes the Data Protection Act 2018, UK GDPR, and the Human Tissue Act, while instruments such as the Adults with Incapacity (Scotland) Act 2000 and the Mental Capacity Act 2005 (England and Wales) apply only where the relevant nation’s remit covers them — a detail sponsors running multi-nation studies frequently miss.

    Frequently Asked Questions

    What is a policy framework?

    A policy framework is a structured set of principles, standards, and accountabilities that organisations must follow within a defined area of activity. In health and social care research, the UK Policy Framework sets 19 such principles covering safety, ethics, transparency, and sponsor accountability, replacing what were previously separate national governance documents.

    What are the ethical frameworks for health research?

    Health research ethics in the UK draws on established principles — autonomy, beneficence, non-maleficence, and justice — operationalised through REC review under the UK Policy Framework. Principles 3, 4, and 12 of the framework specifically require scientifically sound, ethically conducted studies with informed participant choice.

    What are some policies in health and social care?

    Alongside the UK Policy Framework, relevant policies include data protection and confidentiality rules (UK GDPR, Data Protection Act 2018), safeguarding policies, consent and capacity policies, and organisation-specific research governance procedures that translate the framework’s sponsor and REC approval requirements into local practice.

    What are frameworks in healthcare?

    In healthcare, a framework is a formally published document that sets shared expectations for practice across organisations. The UK Policy Framework for Health and Social Care Research is one such framework: a single, UK-wide reference that sponsors, investigators, and NHS/HSC organisations must follow when managing research involving patients or service users.

    Implications for Research Administrators

    For institutional research offices, the framework’s practical weight falls on three activities: confirming sponsorship arrangements before a grant is accepted, tracking REC and HRA/NHS approval milestones against funder timelines, and maintaining the documentation trail — protocols, risk assessments, monitoring reports — that demonstrates ongoing compliance with the 19 principles.

    Bodies such as the Association of Research Managers and Administrators (ARMA) in the UK, and international counterparts including INORMS and NCURA, treat sponsor-duty literacy as a core competency for research administration staff, precisely because sponsor obligations under this framework sit outside the funder’s own grant terms and conditions — a distinction that is frequently misunderstood by newly grant-funded principal investigators.

    A common failure mode is treating “sponsor” and “funder” as synonymous. They are not: a funder can decline the sponsor role entirely, leaving the chief investigator’s employer to accept it, with all the attendant obligations around insurance, monitoring, and public registration described above.

    What This Means Going Forward

    The UK Policy Framework for Health and Social Care Research remains the definitive reference for governance obligations across NHS and HSC research, and its principle-based, proportionate design has held up well against a decade of regulatory change, including UK GDPR and post-Brexit clinical trials reform. For institutions managing grant-funded clinical or social care studies, the operational priority is unchanged: confirm sponsorship early, sequence REC and NHS approval realistically against funder milestones, and keep documentation aligned to the framework’s principles rather than treating it as a one-off compliance checkbox.

    Research administrators seeking to embed these obligations into wider institutional practice may find it useful to review CASRAI’s broader coverage of research administration standards and terminology in the CASRAI Dictionary.

  • Research Misconduct Investigations: How ORI and UKRIO Procedures Compare

    Grant administrators rarely encounter research misconduct allegations often — but when one arrives, the clock starts immediately, and the procedural path depends entirely on which side of the Atlantic the funding sits. A US Public Health Service (PHS) grant triggers a federally regulated process overseen by the Office of Research Integrity (ORI); a UK Research England or UKRI grant triggers an institution-led process shaped, but not enforced, by the UK Research Integrity Office (UKRIO). Confusing the two — assuming ORI’s binding timelines apply to a UK case, or that UKRIO can compel an outcome the way ORI can — is a common and costly error for administrators managing cross-border collaborations.

    This guide sets out, side by side, what each body actually is, how each defines misconduct, and how the investigation stages differ — so administrators handling an allegation tied to a grant know which rulebook applies.

    How ORI and UKRIO define research misconduct

    Both frameworks agree on a common core — fabrication, falsification, and plagiarism (FFP) — but they diverge sharply in scope.

    ORI operates under 42 CFR Part 93, the PHS Policies on Research Misconduct. Its definition is deliberately narrow: research misconduct means fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results. A finding requires three elements to be met: a significant departure from accepted practices in the relevant research community; committed intentionally, knowingly, or recklessly; and proven by a preponderance of the evidence. Honest error and legitimate differences of scientific opinion are explicitly excluded.

    UKRIO, by contrast, works from a broader, non-statutory definition: “behaviours that deliberately or recklessly fall short of the standards expected in the conduct of research.” Its guidance, aligned with the UK Concordat to Support Research Integrity (Universities UK, 2019), extends beyond FFP to cover breaches of ethical approval, undeclared conflicts of interest, and mismanagement of research data — while also naming a distinct, lower-severity category, “questionable research practices” (QRPs), for avoidable errors that fall short of intentional misconduct.

    Regulator versus adviser: two different roles

    The most consequential difference is not definitional but structural: ORI is a federal oversight body; UKRIO is an independent charity with no regulatory power.

    • ORI sits within the US Department of Health and Human Services and directly oversees how institutions handle misconduct allegations tied to PHS-funded research (including NIH grants). It can conduct its own oversight review of an institution’s findings, recommend administrative actions, and refer findings to the HHS Departmental Appeals Board.
    • UKRIO was established as an independent advisory charity in 2006. It publishes a model investigation procedure that UK research organisations may adopt or adapt, offers case-by-case advice, and promotes good practice — but it does not investigate cases itself, does not mandate a single national procedure, and has no statutory sanctioning power.

    UK funders address this gap contractually rather than through a regulator. UKRI’s Guidance for Research Organisations on the Investigation of Research Misconduct (April 2025) requires any organisation receiving UKRI funding to investigate allegations against staff or students under its own Grant Terms and Conditions, with UKRI able to take funding action if an organisation fails to do so.

    How an investigation actually runs, stage by stage

    Both systems separate a preliminary triage stage from a full inquiry, but they name and time these stages differently.

    Stage ORI (US, PHS-funded research) UKRIO model (UK institutions)
    Trigger Allegation received by institution’s Research Integrity Officer Concern raised with a “Named Person” or responsible officer
    Triage Assessment: does the allegation meet the FFP definition and involve PHS funding? Initial assessment: does it fall within the misconduct procedure’s scope?
    Formal fact-finding Inquiry (institution-level, time-limited) Initial investigation to establish if there is a case to answer
    Full review Investigation, following a sufficient inquiry finding Full investigation by an academic panel, including external members
    Standard of proof Preponderance of the evidence Not codified nationally; set by each institution’s procedure
    External oversight ORI oversight review of institutional findings; report to PHS agency None mandatory; UKRIO offers advice only
    Appeal route HHS Departmental Appeals Board Institutional appeal, managed by someone other than the original Named Person

    Under the UKRIO model, once a panel reports its findings, the Named Person decides on next steps: referral to institutional disciplinary proceedings, correction of the published record, and notifying relevant funders. Where allegations are not upheld, the same procedure is meant to protect the reputation of the person accused — a feature both systems share in principle, though neither publishes comparable statistics on false-allegation rates.

    Answer-first: common questions on research misconduct

    What are the three types of research misconduct?

    Both ORI and most UK institutional policies converge on the same core triad: fabrication (inventing data or results), falsification (manipulating research materials, equipment, or data to misrepresent results), and plagiarism (using another person’s ideas, processes, or words without credit). This is often abbreviated FFP.

    What are some examples of research misconduct?

    Common examples include inventing patient consent records, selectively deleting inconvenient data points, copying text or images from another paper without attribution, and misrepresenting the outcome of a statistical test. UKRIO guidance also treats proceeding without required ethical approval as a form of misconduct, even without FFP intent.

    What counts as research misconduct?

    Conduct counts as misconduct when it represents a significant, intentional or reckless departure from accepted research standards — not an honest mistake or a genuine scientific disagreement. ORI requires proof by a preponderance of the evidence; UKRIO-aligned institutions apply a similar intent-based threshold under their own procedures.

    What this means for research administrators

    For administrators managing grants that cross jurisdictions — a common scenario in NIH-funded international collaborations or Horizon Europe partnerships involving UK institutions — three practical points follow from the comparison above:

    • Know which body has enforcement power. Only ORI can conduct oversight review and refer a case to a federal appeals process; UKRIO cannot compel an institutional outcome.
    • Check the funder’s own reporting clause. UKRI’s April 2025 guidance obliges the receiving institution — not UKRIO — to investigate and report; PHS grant terms impose parallel obligations that run through ORI.
    • Do not assume a single global timeline. ORI-regulated inquiries and investigations run to defined federal timeframes; UKRIO-aligned UK procedures are set institution by institution, so the applicable deadline sits in the local Code of Practice for Research, not in UKRIO’s own documents.

    Administrators supporting research administration functions across both systems should hold copies of both the relevant institutional misconduct procedure and the specific grant terms — the procedural detail, not the high-level definition, is where jurisdictional mismatches cause delay.

    Where the two systems are heading

    Both frameworks are converging on the same underlying principle even as their governance models remain distinct: misconduct findings should correct the scholarly record, not just discipline an individual. UKRI’s 2025 guidance tightened institutional reporting obligations, and ORI continues to publish case summaries and administrative actions as a transparency mechanism. Neither change closes the structural gap — one system regulates, the other advises — so for the foreseeable future, administrators handling cross-border allegations will need to work both playbooks rather than assume one substitutes for the other.

    As with contributor-role standards, where CASRAI originated the CRediT taxonomy in 2014 and the standard is now stewarded by NISO as ANSI/NISO Z39.104-2022, research integrity governance illustrates a broader pattern in research administration: originating bodies and enforcement bodies are frequently separate, and knowing which is which is a prerequisite for compliant practice.

  • UKRI Funding Pause 2026: An Administrator’s Planning Calendar

    The UKRI funding pause that unsettled applicant-led research funding in early 2026 is now, council by council, being lifted. UK Research and Innovation suspended several open competitions across the Medical Research Council (MRC) and Biotechnology and Biological Sciences Research Council (BBSRC) while it re-engineered its application infrastructure, and separately paused a set of Engineering and Physical Sciences Research Council (EPSRC) programme grant areas as part of a wider budget reshape. For research offices, the practical question is no longer “what happened” but “when do I need my next round of applications ready” — and that requires a working calendar, not just a news alert.

    What is the UKRI funding pause?

    UKRI announced in January and February 2026 that it was pausing applications to several MRC and BBSRC applicant-led schemes while it moved those councils to an “always open” submission model. The stated rationale, published on UKRI’s own Pauses to funding opportunities page, is that fixed external deadlines create sharp peaks in application volume and reviewer demand; removing them is meant to smooth both.

    The pause sits inside a much larger restructuring. In late 2025, the Department for Science, Innovation and Technology (DSIT) and UKRI set out how £38.6 billion of public R&D funding over four years will be allocated across three new “buckets”: curiosity-driven research, strategic government and societal priorities, and support for innovative companies — each intended to represent roughly 50%, 25% and 25% of spend respectively, according to UKRI chief executive Professor Sir Ian Chapman. Overall UKRI funding is set to rise toward £10 billion a year by 2030, even as individual scheme timelines shift.

    A separate, unrelated cost pressure hit the Science and Technology Facilities Council (STFC), which must deliver £162 million in cost reductions by 2029–30 because of inflation and unfavourable currency exchange rates on international facility costs — prompting project leaders to model reductions of 20%, 40% and 60% to grant lines. UKRI has stated this is a cost-management issue, not a change to the funding model that paused MRC and BBSRC calls.

    Reopening timeline: council by council

    As of UKRI’s most recent update (15 June 2026), most paused schemes have already reopened. The table below consolidates confirmed dates for planning purposes; always cross-check the live UKRI Funding Finder before committing internal deadlines, since UKRI funding service records supersede any secondary summary.

    Council Scheme Status
    MRC Applicant-led research grants Reopened 7 April 2026
    MRC New investigator research grants Reopened 7 April 2026
    MRC Partnership grants Reopened 7 April 2026
    MRC Experimental medicine opportunities Reopened 30 April 2026
    MRC Proof of Concept (formerly Developmental Pathway Funding Scheme) Reopening July 2026
    MRC Impact Acceleration Awards (formerly the Gap Fund) Reopening July 2026
    MRC Fellowships, studentships, Centres of Research Excellence Never paused
    BBSRC New investigator award (applicant-led mode) Reopened
    BBSRC Standard research grant (applicant-led mode) Reopened
    EPSRC Programme grants — energy/decarbonisation, manufacturing/circular economy, quantum technologies Paused at least 12 months from December 2025; no reopening date confirmed

    All other UKRI funding opportunities — across STFC, NERC, ESRC, AHRC, Innovate UK and Research England — continued without interruption throughout the pause. UKRI has consistently described the MRC/BBSRC pauses as short and administrative rather than budgetary.

    Building a submission calendar around funder pauses

    Because the “always open” model removes fixed external deadlines from some schemes while other councils retain calls with hard cut-offs, research offices increasingly need internal, rolling calendars rather than a single annual grants diary. A practical build process:

    • Audit exposure quarterly. List every live application in the pipeline against the specific UKRI funding opportunity ID, not just the council name — pauses have applied to named schemes, not entire councils.
    • Track the Funding Finder, not secondary news. UKRI funding opportunities pages are updated directly when a scheme reopens; sector commentary (LinkedIn, Reddit, trade press) often lags by days or weeks.
    • Buffer internal deadlines. Build a two- to four-week internal review buffer ahead of any reopened scheme’s first post-pause round, since demand typically spikes when a paused call reopens.
    • Flag early-career risk separately. Vitae and Times Higher Education have both warned that even short pauses disproportionately affect early- and mid-career researchers on fixed-term contracts; research offices should track affected individuals, not just projects.
    • Distinguish administrative pauses from budget cuts. The MRC/BBSRC “always open” pause and the STFC cost-reduction exercise are separate processes with different planning implications — do not conflate a scheme reopening with a budget line being restored.

    Answer-first Q&A

    What is the UKRI funding pause?

    The UKRI funding pause refers to UKRI’s temporary suspension of several applicant-led funding opportunities within the MRC and BBSRC in early 2026, while those councils moved to an “always open” application system. It affected named schemes only, not entire council budgets, and most paused calls have since reopened.

    When will paused UKRI funding calls reopen?

    Most MRC applicant-led, new investigator and partnership grants reopened on 7 April 2026, with experimental medicine opportunities following on 30 April 2026. MRC Proof of Concept and Impact Acceleration Awards are scheduled for July 2026. BBSRC’s new investigator and standard research grants have also reopened.

    Which UKRI councils were affected by the funding pause?

    The pause primarily affected the Medical Research Council (MRC) and Biotechnology and Biological Sciences Research Council (BBSRC). Separately, EPSRC paused specific programme grant areas — energy, manufacturing and quantum technologies — for at least 12 months from December 2025. Other councils continued normally.

    How do I check current UKRI funding opportunities?

    Use the official UKRI Funding Finder at ukri.org/opportunity/, which lists every open, upcoming and recently reopened UKRI funding call directly from the UKRI funding service. This is the authoritative source; treat funder pause news coverage as a prompt to check the Finder, not a substitute for it.

    Implications for research offices

    The 2026 episode is a useful stress test of institutional grants administration. Offices that tracked pauses at the individual scheme level, rather than assuming an entire council was closed, were able to keep pipeline applicants moving toward the schemes that stayed open throughout — STFC calls, NERC, ESRC, AHRC and Innovate UK activity were unaffected by the MRC/BBSRC pause. Conversely, offices that paused all outreach on “UKRI funding” as a category lost weeks of preparation time on schemes that never stopped.

    The Campaign for Science and Engineering (CaSE) has separately pressed UKRI for clearer, comparable data on how the new three-bucket allocation model maps to historic research council spending, noting that the shift to “curiosity-driven”, “strategic priorities” and “innovative companies” buckets makes year-on-year comparison difficult. Research administrators building multi-year forecasts should treat pre-2026 allocation figures and post-restructure figures as not directly comparable, per UKRI’s own guidance to the House of Commons Science, Innovation and Technology Committee.

    Outlook for the rest of 2026

    Two threads remain open. First, EPSRC’s paused programme grant areas (energy and decarbonisation, manufacturing and the circular economy, quantum technologies) have no confirmed reopening date and are paused for a minimum of 12 months from December 2025 — institutions with pipeline work in these areas should plan for early 2027 at the earliest. Second, STFC’s £162 million cost-reduction programme runs through 2029–30 and will continue to affect grant, facility and international-collaboration budgets even as the MRC/BBSRC application pause itself is resolved. Research offices should keep these two processes on separate tracks in their planning calendars: one is an application-system change that is largely complete, the other is a multi-year budget exercise still working through its consequences.

    For institutions building longer-range research administration calendars, the practical takeaway from the 2026 pause is procedural: track named schemes via the Funding Finder rather than council-wide status, separate administrative pauses from budget decisions, and maintain a rolling internal deadline buffer for any “always open” scheme rather than relying on a fixed annual cycle.

  • UKRI Policy Fellowships 2026: Embedding Researchers in Government

    What are the UKRI Policy Fellowships 2026

    UK Research and Innovation opened its 2026 call on 9 June 2026, and the UKRI Policy Fellowships 2026 now offer 50 embedded fellowship positions across 26 host partners spanning UK government departments, devolved administrations, arm’s-length bodies and the What Works Network. Each fellowship runs for 18 months and places a researcher directly inside a policy team, working alongside civil servants on live evidence needs rather than producing research at arm’s length.

    The scheme sits within UKRI’s wider fellowship investment framework, which funds researcher mobility between academia and non-academic settings. Unlike a conventional secondment negotiated bilaterally between a university and a government department, the policy fellowships route is a competitive, centrally administered funding call with fixed strands, published cost ceilings and a standard exemplar agreement — details that matter as much to research offices as to the applicants themselves.

    Applications close at 16:00 on Thursday 10 September 2026, submitted through the UKRI Funding Service by the applicant’s employing research organisation.

    Funding strands, amounts and cost-sharing

    The 2026 call is organised into three funding strands, each with its own focus, eligible career stage and full economic cost (FEC) ceiling. UKRI funds 80% of the FEC; the remaining 20% is met by the fellow’s employing research organisation, consistent with the standard UKRI research grant cost-sharing model rather than a fully funded secondment.

    Strand Focus FEC ceiling Career stage
    Core Policy Fellowships Priority areas across UK and devolved government Up to £180,000 Early or mid-career
    What Works Innovation Fellowships Homelessness, policing and place, via the What Works Network Up to £220,000 All career stages
    Natural Hazards and Resilience Fellowships System resilience and preparedness for environmental risk Up to £280,000 Early or mid-career

    Host partners named against these strands include the Department for Business and Trade, the Ministry of Housing, Communities and Local Government, the Scottish Government, the Department of Health and Social Care, the UK Health Security Agency, the Ministry of Justice, the Home Office, the Department for Education, the Cabinet Office, the Environment Agency, the Centre for Homelessness Impact and the Wales Centre for Public Policy, among others. Thematic clusters span economic growth and industrial strategy, health inequalities, justice and public safety, education, housing and place, and the use of data and AI in government.

    Eligibility, key dates and how to apply

    Applicants must hold a doctorate or equivalent research experience, be based at a UKRI-eligible research organisation, and demonstrate subject-matter expertise relevant to a specific fellowship position. UKRI is explicit that career stage is not time-bound by years since doctorate; a researcher without a PhD may still qualify if they can evidence an equivalent sustained research-focused role. Researchers who have already undertaken or are currently undertaking a UKRI policy fellowship are not eligible to reapply.

    • Call opened: 9 June 2026, 09:00
    • Applicant webinar: 25 June 2026
    • Deadline: 10 September 2026, 16:00
    • Shortlisting: October to November 2026
    • Interviews: January 2027
    • Decisions: February 2027
    • Fellowship start: 1 May 2027

    Only the lead research organisation can submit an application to UKRI, though the fellowship agreement itself is negotiated between three parties: the host partner, the fellow, and the employing research organisation. Fellows must also pass any security, nationality and clearance checks the specific host requires before the placement can begin.

    What is the deadline for UKRI Policy Fellowships 2026?

    Applications for the UKRI Policy Fellowships 2026 close at 16:00 on Thursday 10 September 2026, submitted via the UKRI Funding Service. Only the applicant’s lead employing research organisation can make the submission, so institutional sign-off must be secured well before this deadline.

    Who is eligible to apply for UKRI policy fellowships?

    Eligible applicants hold a doctorate or equivalent research experience, are based at a UKRI-eligible research organisation, and meet the early or mid-career descriptor for Core Policy and Natural Hazards strands. What Works Innovation Fellowships are open to researchers at all career stages, including those without a completed doctorate.

    How many UKRI policy fellowship positions are available in 2026?

    UKRI is funding 50 fellowship positions across 26 host partners in the 2026 call, spanning UK government departments, devolved administrations, arm’s-length bodies and What Works Network members. Positions are distributed unevenly across the three funding strands and named host organisations.

    How is UKRI policy fellowship funding structured?

    UKRI funds 80% of the full economic cost of each fellowship, up to strand-specific ceilings of £180,000, £220,000 or £280,000. The employing research organisation covers the remaining 20%, matching UKRI’s standard grant cost-sharing model rather than a fully externally funded secondment.

    How research offices administer secondment agreements and reporting

    For research administrators, the operational detail sits below the headline figures. UKRI requires a formal fellowship or secondment agreement between the host partner, the fellow and the employing research organisation before a placement starts. UKRI has published an exemplar agreement, developed in consultation with UKRI Legal, central government departments and the university sector, and advises institutions to review it well ahead of submission rather than treating it as a post-award formality.

    This has direct implications for how institutions resource the administration of placement schemes:

    • Costing and 20% co-funding sign-off: Because UKRI funds only 80% of FEC, finance teams must confirm the department or faculty can cover the balance before the application is submitted, not after the award is made.
    • Compliance checks: UKRI states plainly that research office and finance teams undertake checks on hosting arrangements and financial eligibility, while ultimate responsibility for compliance remains with the applicant — a split of accountability research offices should document in their own sign-off workflow.
    • Host-specific clearance: Security and nationality checks vary by host department, so administrators cannot rely on a single institutional template; each placement’s clearance requirements need checking against the specific host’s published criteria.
    • Mentor and team roles: Early-career applicants must name a senior mentor from their employing organisation, adding a role that research offices need to track alongside the fellow and the host contact.
    • Reporting during placement: Fellows remain employed by their home institution throughout, so payroll, HR and reporting lines stay with the research organisation even while day-to-day line management sits with the host — a dual-reporting structure that research administration systems must be configured to reflect.

    This three-way agreement structure — host, fellow, employer — is the genuine administrative distinction of the UKRI scheme compared with informally negotiated academic-government exchanges, and it is the detail most coverage of the 2026 call omits in favour of headline position and funding counts.

    Implications for institutions and applicants

    Research offices supporting an applicant should treat the fellowship agreement review as a parallel workstream to the academic proposal, not a downstream task. Given the FEC ceilings scale with strand rather than individual placement complexity, institutions should also confirm early whether their standard overhead recovery models accommodate an 80/20 split embedded within a government host, rather than a conventional university-based grant.

    Applicants working with sensitive or linked administrative datasets should note that feasibility assessments — including secure data access approvals — need to be scoped against the 18-month fellowship window from the outset, since data access timelines can otherwise outrun the placement itself.

    Outlook: what happens after the September deadline

    With shortlisting running October to November 2026, interviews in January 2027 and a fellowship start date of 1 May 2027, institutions have a multi-month gap between submission and confirmed placement — a window research offices can use to finalise co-funding approvals, mentor arrangements and host-specific clearance paperwork rather than leaving them until decisions land. As UKRI continues to expand policy fellowship strands beyond their original remit, research administrators are likely to see this three-party agreement model applied to further embedded-researcher schemes, making early familiarity with the exemplar agreement a transferable skill rather than a one-off task.

  • NIH Grant Terminations in 2026: What Was Cancelled, What Was Restored, and Why

    What happened: the 2025-2026 NIH termination wave

    Beginning in March 2025, the National Institutes of Health cancelled thousands of active research awards in one of the largest disruptions to federal biomedical funding in decades. A peer-reviewed analysis published in the Proceedings of the National Academy of Sciences in 2026 counted 2,291 active NIH research grants terminated in the initial wave, withdrawing an estimated $2.45 billion in committed funding. NIH grant terminations continued through the spring, and by late May 2025 Harvard T.H. Chan School of Public Health researchers tracking the cuts put the cumulative total at roughly 2,100 grants worth approximately $9.5 billion.

    Independent counts diverged because institutions and awarding offices reported figures at different points in a fast-moving process. The Association of American Medical Colleges recorded 777 terminated grants representing $1.9 billion as of 5 May 2025, while an implementation-science analysis published in PubMed Central counted 702 terminations as of 5 April 2025. The variance reflects the pace of the cuts rather than disagreement about their occurrence.

    Which grants and research topics were targeted

    Termination notices sent to grantees cited a shift in agency funding priorities away from topics the administration characterised as “unscientific” or as promoting discrimination. Research areas disproportionately affected included:

    • LGBT+ health and gender-identity research
    • Diversity, equity, and inclusion (DEI) initiatives in the biomedical workforce
    • Vaccine hesitancy and confidence studies
    • Health equity and racial health-disparities research
    • Climate change and environmental-health research

    Reporting by Applied Clinical Trials Online found that 20% of terminated grants were early-career training awards, a category central to sustaining the biomedical research pipeline. A subsequent analysis found the cuts fell disproportionately on Black, Indigenous, and other minority researchers, as well as investigators from sexual and gender-minority communities — a pattern that later became central to the legal challenges against the terminations.

    Court-ordered restorations: the timeline

    Multiple lawsuits challenged the terminations as procedurally unlawful and discriminatory. The table below summarises the major rulings tracked through mid-2026.

    Date Ruling / event Outcome
    16 June 2025 Judge William Young (D. Mass.), APHA v. NIH Ordered NIH to restore 367 grants worth nearly $3.8 billion; found the termination process “arbitrary and capricious” and discriminatory toward LGBTQ-related research
    25 June 2025 NIH response to court order NIH ceased issuing new terminations of “politically sensitive” grants while the ruling was contested
    August 2025 Federal court order, UCLA class action Ordered restoration of NSF grants suspended at UCLA from 1 August 2025
    September 2025 Federal court order, UCLA Ordered restoration of NIH funding suspended at UCLA from 31 July 2025; NIH reinstated the awards
    May 2026 Ninth Circuit Court of Appeals Upheld reinstatement of grants terminated under DEI- and environmental-justice-related executive orders, the first major appellate ruling on the issue

    The Department of Health and Human Services has pursued appeals against several of these rulings, so the restoration list is not static. Institutions should treat any given month’s figures as a snapshot rather than a final count.

    Answer-first: common questions about NIH grant terminations

    How many NIH grants have been terminated?

    Counts vary by source and date because the terminations rolled out over several months. Published figures range from 702 grants in early April 2025 to 2,291 grants worth $2.45 billion in the fullest peer-reviewed accounting, published in PNAS in 2026.

    Have any terminated NIH grants been restored?

    Yes. A federal judge ordered 367 grants restored in June 2025 following the APHA v. NIH ruling, and separate court orders restored NIH and NSF funding to UCLA researchers later that year. In May 2026 the Ninth Circuit Court of Appeals upheld further reinstatements.

    How can a research office check if a specific NIH grant was terminated?

    Research offices should cross-check award numbers against NIH RePORTER, the HHS TAGGS terminated-grants list, and USASpending.gov, then corroborate against the crowdsourced Grant Watch database, which aggregates termination notices submitted directly by affected principal investigators.

    What is the Grant Watch database?

    Grant Watch is an independent tracker built by Harvard T.H. Chan School of Public Health researcher Scott Delaney and computational researcher Noam Ross, combining government data with crowdsourced submissions to document NIH and NSF grant terminations that agency reporting has not consistently disclosed.

    Monitoring exposure: RePORTER, TAGGS, and tracker databases

    For sponsored-programmes offices, the operational question is not just what happened nationally but which of an institution’s own awards are exposed. No single federal system currently gives a real-time, authoritative picture of terminations and restorations together, so offices need to triangulate across sources.

    Tool Custodian Best for
    NIH RePORTER National Institutes of Health Authoritative award status, PI, institution, and funding history lookups
    HHS TAGGS (terminated-grants list) U.S. Department of Health and Human Services Official, periodically updated PDF/CSV of terminated HHS awards by agency
    USASpending.gov U.S. Treasury / OMB Government-wide obligation and de-obligation records across all federal awards
    Grant Watch Independent researcher-run project Early, crowdsourced signal on terminations before official lists update

    A practical monitoring routine for a research office includes:

    1. Reconcile the institution’s active award list against NIH RePORTER monthly, flagging any status changes.
    2. Cross-check flagged awards against the HHS TAGGS terminated-grants file for confirmation of formal termination.
    3. Monitor Grant Watch and institutional legal counsel updates for early warning and litigation status, since court-ordered restorations can lag or precede official RePORTER updates.
    4. Maintain a standing register of affected PIs so restoration notices — which are sometimes issued quietly — are not missed.

    Because restorations have followed litigation rather than routine agency process, research offices that rely solely on award letters risk missing reinstatements that require the institution to formally re-accept funding within a compliance window. Building this monitoring into research administration workflows, rather than treating it as a one-off compliance exercise, is now a standing requirement for institutions with federally funded portfolios.

    Implications for institutions, PIs, and research offices

    The termination-and-restoration cycle has practical consequences beyond the immediate funding gap. Institutions have had to decide whether to bridge-fund affected projects, hold staff and data-collection activities in limbo, or wind down studies that may later be reinstated. Early-career researchers, who held a disproportionate share of terminated training awards, face particular career risk from even temporary funding gaps.

    The pattern of litigation-driven reinstatement also means compliance offices cannot treat a termination notice as final without checking litigation status — a departure from how terminations were historically administered. As appellate rulings such as the May 2026 Ninth Circuit decision accumulate, research offices should expect further reinstatements to arrive on a rolling basis rather than as a single resolution, making ongoing monitoring — not a one-time audit — the operationally necessary posture through the remainder of 2026.

  • NIH Reinstates South Africa Grant Funding: Inside the Subaward Policy Reversal

    The US National Institutes of Health (NIH) has reinstated South Africa grant funding that had been frozen for months, lifting a hold on payments for scores of existing awards after a policy change nearly collapsed one of its largest overseas HIV and tuberculosis research partnerships. The reversal does not undo the underlying policy — a ban on new foreign subawards — but it restores cash flow to active clinical trials and signals how the NIH intends to manage international collaboration going forward.

    For research administrators, sponsored-programs offices, and institutional leaders outside the United States, the episode is a case study in how quickly a funder’s compliance architecture can change, and how little advance notice foreign partners typically get.

    What happened: the subaward ban and its fallout

    On 1 May 2025, the NIH announced it would no longer permit foreign “subawards” — the standard mechanism by which a US-based principal investigator holding a “prime” NIH grant channels a portion of the funds to a collaborating institution abroad. Going forward, foreign partners would instead need to apply for direct awards from the NIH itself.

    The agency framed the change as an effort to improve financial tracking and safeguard national security. In practice, the shift landed on a system that was not ready for it: the NIH’s own staff guidance warned that the infrastructure for processing direct foreign awards might not be operational until 30 September 2025.

    South Africa was disproportionately exposed. The country hosts one of the NIH’s largest overseas research footprints, particularly in HIV and TB clinical trials run through institutions such as the University of the Witwatersrand and the South African Medical Research Council (SAMRC). Disruption had begun even earlier: in March 2025, the NIH moved to freeze or terminate roughly 280 grants tied to South African projects, well before the formal subaward ban took effect.

    The scale of the exposure was significant. In the prior funding year, the NIH had supported approximately 3,600 subawards in foreign countries worth more than $400 million in total. South African institutions alone had been receiving an estimated $100–150 million a year in direct and sub-awarded NIH funding, according to analysis published by Physicians for Human Rights.

    Timeline: from termination to reinstatement

    The sequence of events matters for any institution assessing exposure to future funder policy shifts. The table below sets out the key dates drawn from contemporaneous reporting.

    Date Development
    March 2025 NIH moves to freeze or terminate roughly 280 grants for South African projects
    1 May 2025 NIH formally bans new foreign subawards; requires direct-award applications instead
    27 June 2025 NIH grants official Michelle Bulls confirms existing clinical-research subawards can continue via a new “supplement” mechanism; roughly 100 prime awards to South African researchers permitted to proceed
    30 June 2025 Staff guidance carves out an exception for human-subjects research submitted before the ban
    July 2025 NIH lifts the payment hold on scores of existing South Africa grants, without public explanation
    30 September 2025 (target) NIH’s new direct-award tracking system for foreign partners due to be operational

    Notably, the reinstatement applied to grants that had been frozen, not to the larger population of grants that had been fully terminated. Separately, the NIH has also been under court order to reinstate a portion of the more than 2,000 grants it cancelled nationwide over politically sensitive research topics — a distinct, US-domestic dispute that runs in parallel to the foreign-subaward story.

    Key questions answered

    Have NIH grants been reinstated?

    Yes, partially. In July 2025 the NIH lifted a payment hold on scores of existing South Africa grants and introduced a “supplement” mechanism letting foreign clinical-research subawards continue. It remains unclear whether grants that were fully terminated, rather than merely frozen, will also be restored.

    How many NIH grants have been canceled?

    Across all research areas, the federal government terminated approximately 2,100 NIH grants worth around $9.5 billion, according to tracking by Harvard T.H. Chan School of Public Health. Within that total, roughly 280 South Africa-linked grants were separately frozen or ended starting in March 2025.

    Do South African universities face a funding crisis from the freeze?

    Yes. Institutions including the University of Cape Town and Wits University reported severe financial strain, staff layoffs, and applications for emergency government funding — with the Wits Health Consortium reportedly seeking over R1.8 billion from South Africa’s Treasury to offset the shortfall.

    What it means for foreign subawardees and research offices

    The reversal is narrow, temporary, and administratively burdensome — not a return to the pre-2025 status quo. Institutions that rely on NIH funding through US-based collaborators should treat the following as durable changes rather than transient disruption:

    • Subawards are being phased out for new and renewal applications. The direct-award model is now the NIH’s default path for foreign partners, and institutions should build direct-application capacity rather than assuming subaward continuity.
    • The supplement mechanism is a stopgap, not a policy. An NIH grants official described the conversion process as “a huge administrative lift” — sponsored-programs offices should expect delays and duplicated paperwork during the transition period.
    • Frozen and terminated are legally distinct categories. Institutions holding terminated (not just frozen) awards should not assume the July reinstatement applies to them without written confirmation from their program officer.
    • Compliance offices need contingency plans. Bodies such as NCURA, EARMA, and ARMA have flagged funder-driven subaward volatility as a growing risk category for institutional research administration — not unique to the NIH or to South Africa.

    For research administration teams managing sponsored programmes with US federal funders, the practical lesson is procedural: subaward agreements should now include explicit clauses addressing funder-initiated conversion to direct awards, and institutions should maintain the internal capacity to submit direct NIH applications on short notice.

    What to track going forward

    Three open questions will determine whether this remains a contained South Africa story or a template applied more broadly to NIH’s international grant portfolio.

    First, whether the 30 September 2025 target for a functioning direct-award tracking system holds, or whether the interim supplement mechanism becomes a permanent parallel process. Second, whether the reinstatement logic extends to grants that were fully terminated rather than frozen — a distinction the NIH has not yet resolved publicly. Third, whether other major NIH partner countries in HIV, TB, and global-health research face the same subaward-to-direct-award transition South Africa has already been through.

    For institutions with NIH-funded international partnerships, the prudent posture is to document funder communications carefully, confirm award status (frozen versus terminated) in writing, and monitor NIH policy notices for extensions or modifications to the direct-award transition timeline.

  • Cooperative Agreement vs Grant: What the Law Actually Requires

    Every research administrator eventually meets an award letter that does not say “grant” at the top. Understanding a cooperative agreement vs grant distinction is not academic housekeeping — it determines who signs off on your data collection plan, how often you report, and whether a federal programme officer can direct the day-to-day conduct of your funded work. The dividing line was set in US law nearly fifty years ago, and it still governs every award letter issued by NSF, NIH, DOE, USDA and dozens of other federal agencies.

    The Federal Grant and Cooperative Agreement Act of 1977 (Public Law 95-224, codified at 31 U.S.C. §§6301–6308) requires every executive agency to classify a funding relationship as one of three legal instruments before it awards money: a procurement contract, a grant agreement, or a cooperative agreement.

    The statute draws the line on two questions, applied in sequence:

    • Is the government acquiring something for its own direct benefit? If yes, the instrument must be a procurement contract under 31 U.S.C. §6303, governed by the Federal Acquisition Regulation (FAR).
    • If the purpose is instead to support or stimulate a public activity, is “substantial involvement” expected between the agency and the recipient? If no, it is a grant agreement (31 U.S.C. §6304). If yes, it is a cooperative agreement (31 U.S.C. §6305).

    Both grants and cooperative agreements are forms of federal financial assistance and sit under the Office of Management and Budget’s Uniform Guidance at 2 CFR Part 200, not the FAR. That single fact explains why grants and cooperative agreements share so much administrative machinery — standard forms, cost principles, audit requirements — while contracts follow an entirely separate acquisition regime.

    Grant vs cooperative agreement vs contract: the three-way test

    The clearest way to see the distinction is side by side. The table below reflects the statutory test as applied consistently across federal science agencies, including the framework published by the US Department of Energy’s Office of Science.

    Feature Grant Cooperative agreement Procurement contract
    Statutory basis 31 U.S.C. §6304 31 U.S.C. §6305 31 U.S.C. §6303
    Purpose Support/stimulate a public activity Support/stimulate a public activity Acquire goods/services for the government
    Federal involvement Oversight and stewardship only “Substantial involvement” expected Direction and control of delivery
    Governing rules 2 CFR Part 200 (Uniform Guidance) 2 CFR Part 200 (Uniform Guidance) Federal Acquisition Regulation
    Who owns the IP Recipient, typically Recipient, typically May transfer to government
    Scope of work Defined by applicant/PI Negotiated jointly Defined by the sponsoring agency

    A cooperative agreement therefore sits between a grant and a contract without being either. It is a financial assistance award — like a grant — but the awarding agency retains an active, defined role in carrying out the funded activity, which is the hallmark of a contract relationship without the acquisition purpose that would make it one.

    Answer-first: common questions on cooperative agreements

    What is a cooperative agreement?

    A cooperative agreement is a legal instrument of federal financial assistance used when an agency expects “substantial involvement” in a project it is funding for a public purpose. Unlike a grant, the agency actively participates — reviewing milestones, coordinating sub-awards, or contributing technical direction — rather than simply monitoring progress from a distance.

    What is the difference between a grant agreement and a contract?

    A grant transfers value to support a public purpose the recipient defines and controls; a contract acquires goods or services for the government’s direct benefit under terms the government specifies. Grants follow Uniform Guidance cost principles; contracts follow FAR-based competition, protest, and deliverable-acceptance rules.

    What is the difference between a grant and a cooperative agreement?

    Both are financial assistance instruments for public-purpose activities, but a cooperative agreement requires anticipated substantial federal involvement — joint design, resource allocation across sites, or active participation in research conduct — while a grant assumes the recipient carries out the work with only routine agency oversight.

    Is a cooperative agreement legally binding?

    Yes. A federal cooperative agreement is a binding award under 31 U.S.C. §6305 with enforceable terms, reporting obligations, and audit exposure. Do not confuse it with a private-sector “cooperation agreement” between two companies — a different, non-statutory instrument that follows ordinary contract law rather than federal assistance regulation.

    Why the distinction matters for research administrators

    The choice of instrument is not cosmetic; it changes real obligations for every principal investigator and sponsored-programmes office.

    • Reporting cadence and content. Cooperative agreements typically carry more frequent, and more detailed, progress reporting than a comparable grant, because the agency needs current information to exercise its involvement rights.
    • Prior-approval requirements. Where a grant might allow a principal investigator to reallocate budget or change key personnel within defined limits without agency sign-off, a cooperative agreement more often requires the agency’s prior approval at defined decision points.
    • Programmatic authority. Under a cooperative agreement, an agency programme officer may participate in study design, site selection, or data-sharing decisions — participation that would be inappropriate, and potentially instrument-converting, under a grant.
    • Audit and subrecipient monitoring. Both instruments sit under Uniform Guidance audit requirements, but the active federal role in a cooperative agreement often means closer scrutiny of how funds move to subrecipients and consortium partners.

    NSF cooperative agreement awards illustrate the pattern well. The National Science Foundation uses cooperative agreements — rather than grants — for its large research infrastructure programmes, including major facilities where NSF staff are directly engaged in oversight of construction, operations, and multi-institution coordination. The same NSF portfolio uses ordinary grants for the vast majority of individual investigator-led research, where the Foundation’s role is genuinely limited to stewardship.

    This is also where the distinction between grant administration vs grant management becomes practically important. Grant administration — the institutional function performed by a sponsored-programmes or research-administration office — covers pre-award compliance review, negotiation of terms, and post-award financial and regulatory oversight, and it must flex significantly for a cooperative agreement’s heavier approval and reporting load. Grant management, by contrast, is the principal investigator’s day-to-day delivery of the funded work. Bodies such as NCURA, EARMA, ARMA and INORMS increasingly treat instrument classification as a first checkpoint in research administration training precisely because misclassifying an award — or failing to staff for a cooperative agreement’s collaborative obligations — creates downstream compliance risk that a standard grant checklist will not catch.

    Institutions building out their research administration compliance frameworks should treat instrument type as a triage question at intake, not an afterthought discovered mid-project when a programme officer asks to review a dataset before publication.

    Looking ahead

    The Federal Grant and Cooperative Agreement Act has not been substantively rewritten since 1977, but its “substantial involvement” test is being tested constantly by newer funding models — public-private consortia, multi-agency infrastructure awards, and international collaborations that blend federal and non-federal sponsors. As funders experiment with more collaborative funding structures, research administrators who can correctly classify an instrument at the proposal stage — and staff accordingly — will be better placed to meet reporting obligations and protect institutional standing than those who treat “grant” as a catch-all label for any federal award. Consulting authoritative terminology resources, including a controlled research administration dictionary, helps ensure proposal teams and compliance offices are using these terms consistently across an institution.